infect
solid
organ
transplant
critic
care
intens
care
unit
icu
sepsi
solid
organ
transplant
recipi
complex
group
patient
requir
low
threshold
suspicion
regard
infect
given
underli
immunosuppress
mortal
morbid
high
individu
requir
assess
net
state
immunosuppress
subsequ
thorough
evalu
infecti
caus
earli
diagnosi
key
along
appropri
tailor
treatment
crit
care
clin
immunosuppress
play
integr
role
solid
organ
transplant
sot
recipi
increas
graft
surviv
howev
unintend
consequ
infecti
complic
one
strategi
aim
assess
function
immun
system
consist
nonpathogenspecif
immun
monitor
consist
serum
immunoglobulin
serum
complement
factor
peripher
blood
lymphocyt
subpopul
solubl
iatp
cell
ideal
would
help
demonstr
one
aspect
overal
net
state
immunosuppress
net
state
immunosuppress
compris
factor
may
contribut
risk
infect
includ
preexist
immun
deficit
colon
antimicrobialresist
pathogen
immunosuppress
agent
acquir
immunodefici
prior
antimicrobi
therapi
mucocutan
barrier
integr
fluid
collect
neutropenia
lymphopenia
viral
coinfect
disclosur
statement
guenett
relationship
commerci
compani
direct
financi
interest
subject
matter
materi
discuss
articl
compani
make
compet
product
husain
receiv
grant
astella
pfizer
merck
divis
infecti
diseas
univers
health
network
univers
toronto
univers
avenu
vaccin
surgic
prophylaxi
univers
prophylaxi
preemptiv
presymptomat
therapi
target
prophylaxi
educ
avoid
prevent
strategi
implement
sot
recipi
trimethoprimsulfamethoxazol
prophylaxi
given
institut
month
lifetim
prevent
pneumocysti
pneumonia
along
toxoplasma
gondii
cyclospora
cayetanensi
mani
nocardia
listeria
speci
antivir
prophylaxi
along
nucleic
acidbas
assay
prevent
cytomegaloviru
cmv
herpesviru
infect
also
transform
posttranspl
care
infect
sot
recipi
reflect
net
balanc
recipi
epidemiolog
exposur
immunosuppress
alter
balanc
seen
antimicrobi
prophylaxi
immunosuppress
improv
graft
surviv
balanc
also
affect
period
graft
reject
intensif
immunosuppress
fig
articl
author
review
infecti
syndrom
encount
intens
care
unit
among
sot
recipi
bloodstream
infect
bsi
associ
poor
outcom
along
lead
caus
mortal
morbid
sot
mortal
high
describ
fact
septic
shock
develop
mortal
reach
although
kalil
colleagu
demonstr
may
decreas
mortal
transplant
patient
compar
nontranspl
patient
thought
sot
recipi
necessarili
clinic
behav
manner
due
underli
immunosuppress
fact
tend
present
organ
failur
thrombocytopenia
sepsi
univers
risk
factor
sepsi
regardless
transplant
organ
cmv
serolog
mismatch
particularli
posit
donor
neg
recipi
cmv
diseas
inher
demonstr
immunomodulatori
effect
predispos
recipi
higher
rate
bacteri
fungal
sepsi
prolong
durat
graft
cold
ischemia
prolong
durat
surgic
transplant
procedur
requir
larg
amount
blood
transfus
manag
consist
rapid
initi
intraven
antibiot
rapid
diagnosi
sourc
control
aggress
search
patholog
condit
mimic
sever
sepsi
reduct
immunosuppress
drug
nosocomi
bsi
associ
even
increas
risk
septic
shock
failur
cure
compar
bsi
sot
patient
gramposit
bacteria
frequent
sourc
bsi
like
associ
intravascular
cathet
especi
nosocomi
set
howev
kidney
transplant
recipi
ktr
gramneg
bacteria
like
relat
urinari
tract
infect
uti
primari
sourc
regardless
time
period
overal
incid
multidrugresist
organ
mdro
increas
mdro
gramneg
organ
account
isol
fluconazoleresist
candida
spp
account
case
candidemia
accord
moreno
colleagu
vancomycinresist
enterococci
vre
becom
emerg
pathogen
studi
document
incid
nosocomi
enterococc
spp
bsi
consist
vre
find
along
previou
microbiolog
histori
local
antibiot
resist
pattern
consid
determin
empir
antimicrobi
therapi
overal
limit
studi
infect
endocard
ie
sold
organ
transplant
recipi
incid
ie
singl
center
estim
higher
incid
compar
gener
popul
overal
mortal
limit
data
mode
infect
predispos
factor
sot
recipi
underli
structur
abnorm
may
appear
risk
factor
ie
compar
gener
popul
accord
paterson
colleagu
infect
due
aspergillu
fumigatu
staphylococcu
aureu
due
viridan
streptococci
contrast
gener
popul
combin
antibiot
therapi
describ
infecti
diseas
societi
america
idsa
guidelin
infect
endocard
adult
diagnosi
antimicrobi
therapi
manag
complic
surgic
manag
warrant
current
manag
empir
manag
suspect
sepsisbsi
includ
gramposit
coverag
presenc
intravascular
cathet
broad
gramneg
coverag
choic
antibiot
depend
local
epidemiolog
previou
microbiolog
data
empir
candida
antifung
coverag
requir
earli
initi
antifung
shown
improv
outcom
random
control
trial
mostli
immunocompet
patient
bacteri
pneumonia
common
caus
lower
respiratori
tract
infect
accord
giannella
colleagu
communityacquir
pneumonia
cap
found
hospitalacquir
pneumonia
hap
found
sot
recipi
treat
pneumonia
lung
transplant
recipi
bacteri
pneumonia
bronchiti
account
infect
incid
bacteri
pneumonia
peak
first
postop
week
declin
fourth
month
periop
antibiot
focus
preoper
cultur
recipi
donor
reduc
incid
earli
bacteri
pneumonia
less
regard
cardiac
hepat
renal
transplant
incid
earli
bacteri
pneumonia
respect
mortal
liver
kidney
transplant
recipi
howev
mortal
nosocomi
communityacquir
infect
extrem
compar
mechan
ventil
nosocomi
infect
higher
increas
risk
death
initi
periop
infecti
complic
period
nosocomi
pathogen
pseudomona
aeruginosa
escherichia
coli
klebsiella
speci
acinetobact
speci
aureu
includ
methicillinresist
aureu
mrsa
consid
immedi
periop
period
howev
prolong
mechan
ventil
follow
transplant
increas
risk
nosocomi
pneumonia
communityacquir
pathogen
haemophilu
influenza
streptococcu
pneumonia
legionella
speci
may
seen
implement
trimethoprimsulfamethoxazol
prophylaxi
incid
nocardia
pneumonia
decreas
howev
still
report
empir
treatment
take
consider
previou
microbiolog
data
local
epidemiolog
recent
clinic
histori
regard
empir
antibiot
coverag
respiratori
viral
infect
signific
caus
mortal
morbid
among
transplant
recipi
includ
influenza
respiratori
syncyti
viru
parainfluenza
viru
rhinoviru
human
metapneumoviru
coronaviru
season
pattern
usual
follow
gener
public
diseas
consist
mild
congest
rhinorrhea
sever
tracheobronch
bronchiol
pneumonia
clinic
manifest
rang
mild
atyp
symptom
includ
absenc
fever
lung
transplant
recipi
present
sever
clinic
cours
complic
viral
shed
usual
prolong
seen
even
use
antivir
transplant
recipi
higher
risk
infecti
complic
includ
fungal
bacteri
pneumonia
respiratori
viral
infect
appear
risk
factor
acut
chronic
reject
especi
lung
transplant
recipi
diagnost
workup
consist
nasopharyng
swab
wash
aspir
upper
tract
sampl
fail
document
caus
clinic
radiolog
evid
lower
tract
involv
bronchoalveolar
lavag
bal
consid
polymeras
chain
reaction
pcr
base
assay
commerci
avail
mani
center
adopt
prefer
mode
test
given
high
sensit
along
allow
simultan
detect
broad
rang
respiratori
pathogen
singl
sampl
treatment
outlin
fig
includ
support
care
reduct
immunosuppress
adenoviru
nonenvelop
lytic
doublestrand
dna
viru
acquir
de
novo
reactiv
latent
infect
recipi
transplant
organ
transmiss
occur
respiratori
rout
persontoperson
contact
fecalor
rout
true
incid
among
sot
recipi
unknown
infect
occur
within
first
year
transplant
clinic
manifest
vari
howev
affect
lung
transplant
recipi
produc
rang
clinic
manifest
includ
acut
flulik
ill
diffus
alveolar
damag
necrot
pneumonia
along
chronic
chang
bronchiol
obliteran
interstiti
fibrosi
bronchiectasi
viral
cultur
direct
antigen
detect
molecular
method
histopatholog
avail
diagnosi
histopatholog
evalu
gold
standard
diagnosi
invas
diseas
rapid
antigen
detect
kit
particular
immunofluoresc
assay
process
respiratori
specimen
commerci
avail
yield
rapid
specif
result
pcr
qualit
quantit
emerg
wide
use
tool
detect
highli
sensit
rapid
recoveri
adenoviru
respiratori
sampl
necessarili
confirm
diseas
patient
shed
asymptomat
prolong
period
time
therefor
essenti
correl
clinic
find
along
detect
viru
site
histopatholog
find
cidofovir
best
evid
support
use
treatment
adenovir
infect
brincidofovir
lipid
conjug
cidofovir
also
demonstr
vitro
suscept
appear
promis
vivo
regard
sot
recipi
howev
studi
warrant
cmv
major
pathogen
sot
recipi
abil
caus
endorgan
diseas
immunomodulatori
effect
cmv
impair
tcell
phagocyt
function
cytokin
dysregul
lead
opportunist
infect
reject
graft
loss
reduc
surviv
transplant
recipi
highest
risk
seroneg
recipi
seroposit
organ
preexist
immun
seroposit
recipi
intermedi
risk
littl
differ
group
potenti
wors
outcom
fig
clinic
present
consist
dyspnea
fever
malais
identif
characterist
cmv
cell
lung
tissu
radiograph
chang
nonspecif
includ
diffus
hazi
focal
hazi
focal
lobar
consolid
chang
diagnosi
made
via
cell
cultur
viral
isol
howev
time
consum
therefor
detect
cmv
dna
pcr
peripher
blood
leukocyt
provid
sensit
specif
cmv
pneumon
along
bal
cmv
dna
pcr
altern
mean
diagnosi
howev
regard
bal
find
would
imper
differenti
infect
versu
shed
henc
concomit
peripher
blood
leukocyt
pcr
along
clinic
pictur
necessari
help
determin
diagnosi
treatment
consist
ganciclovir
oral
altern
valganciclovir
foscarnet
cidofovir
altern
option
howev
primarili
reserv
concern
resist
document
resist
sideeffect
profil
less
desir
cmv
immunoglobulin
conjunct
treatment
offer
limit
efficaci
maribavir
brincidofovir
letermovir
novel
agent
may
provid
altern
option
treatment
howev
studi
warrant
candida
frequent
colon
lung
transplant
recipi
less
patient
colon
develop
invas
diseas
bronchial
anastomot
infect
may
occur
earli
postop
set
lead
anastomot
failur
parenchym
lung
infect
mediastin
artifici
bronchial
stent
serv
potenti
site
infect
candida
tracheobronch
base
visual
inspect
histolog
confirm
along
posit
cultur
appropri
specimen
aspergillu
speci
saprophyt
organ
higher
rate
mortal
incid
lung
heart
liver
kidney
transplant
recipi
infect
may
due
reactiv
de
novo
infect
follow
inhal
mold
renal
failur
hemodialysi
repeat
bacteri
infect
leukopenia
cmv
diseas
high
level
immunosuppress
retransplant
chronic
exposur
transplant
lung
environ
abnorm
anatom
physiolog
function
transplant
still
present
nativ
lung
airway
ischemia
hypogammaglobulinemia
cystic
fibrosi
bronchial
stent
risk
factor
invas
aspergillosi
lung
transplant
recipi
colon
aspergillu
complic
infect
affect
patient
colon
also
lead
bronchiol
obliteran
syndrom
lung
transplant
clinic
manifest
rang
asymptomat
colon
tracheobronch
invas
pulmonari
aspergillosi
empyema
dissemin
diseas
symptom
includ
purul
sputum
fever
malais
respiratori
distress
hemoptysi
aspergillu
tracheobronch
caus
airway
obstruct
ulcer
pseudomembran
format
nonaspergillu
myceli
fungi
also
increas
frequenc
high
overal
mortal
howev
zygomycosi
rhizopu
mucor
speci
nonaspergillu
hyalohyphomycosi
scedosporium
apiospermum
fusarium
speci
even
higher
mortal
endem
fungi
coccidioid
immiti
histoplasma
capsulatum
blastomyc
dermatitidi
cryptcoccu
addit
pathogen
may
need
consid
radiolog
find
may
demonstr
nodul
cavitari
lesion
focal
consolid
patchi
densiti
wedgeshap
pleuralbas
lesion
airfil
bronchi
intralumin
lesion
air
crescent
sign
halo
decreas
densiti
tissu
invas
fungal
organ
gold
standard
diagnosi
invas
fungal
pneumonia
howev
may
difficult
obtain
therefor
intern
societi
heart
lung
transplant
develop
guidelin
work
formul
standard
definit
infect
cardiothorac
transplant
recipi
assist
diagnosi
fungal
infect
also
bacteri
viral
infect
definit
may
also
appli
abdomin
transplant
recipi
treatment
follow
fig
howev
awar
drugdrug
interact
regard
immunosuppress
agent
import
note
howev
empir
manag
mold
infect
sot
recipi
seldom
necessari
optim
approach
pursu
diagnost
workup
aggress
treat
accordingli
even
lung
transplant
recipi
pneumocysti
jirovecii
gondii
mycobacterium
tuberculosi
nontuberculosi
mycobacteria
pathogen
also
consid
possibl
caus
respiratori
tract
infect
along
pathogen
list
fig
central
nervou
system
cn
infect
account
approxim
cn
lesion
transplant
recipi
routin
prophylaxi
aim
opportunist
infect
along
conserv
approach
regard
immunosuppress
led
notic
trend
infect
transplant
recipi
exampl
routin
administr
trimethoprimsulfamethoxazol
p
jirovecii
like
contribut
reduct
infect
owe
gondii
nocardia
listeria
monocytogen
along
acyclovir
valganciclovir
attribut
like
declin
herpesviridaerel
infect
clinic
present
vari
may
includ
fever
headach
meningismu
kernig
brudzinski
sign
newonset
seizur
papilledema
alter
sensorium
andor
focal
neurolog
deficit
howev
underli
immunosuppress
may
subtl
absent
list
fig
possibl
caus
rang
communityacquir
organ
donorderiv
infect
reactiv
opportunist
pathogen
metastat
direct
lesion
along
pulmonarybrain
syndrom
also
consider
organ
cryptococcu
nocardia
aspergillu
zygomycet
strongyloid
toxoplasma
therefor
investig
warrant
eg
comput
tomographi
sinu
comput
tomographi
chest
evalu
includ
neuroimag
along
lumbar
punctur
soon
possibl
contraind
exist
cerebr
spinal
fluid
examin
alway
includ
cell
count
differenti
glucos
protein
routin
smear
cultur
bacteria
fungi
mycobacteria
addit
special
test
viral
pcr
antigen
antibodi
ribosom
rna
may
requir
depend
clinic
scenario
howev
brain
biopsi
appropri
stain
may
definit
diagnosi
find
inconclus
empir
treatment
cover
common
bacteri
viral
pathogen
howev
addit
agent
may
need
depend
epidemiolog
histori
cholang
common
infect
liver
transplant
fact
common
infect
year
liver
transplant
case
occur
within
year
associ
primari
scleros
cholang
rouxeni
anastomosi
frequent
identifi
bacteria
enterococcu
spp
e
coli
howev
gramneg
bacilli
anaerob
also
consid
bile
leak
occur
case
liver
transplant
especi
live
liver
donor
transplant
clinic
present
vari
extent
leak
howev
symptom
includ
abdomin
pain
fever
sign
periton
howev
underli
immunosuppress
also
asymptomat
case
elev
serum
bilirubin
fluctuat
cyclosporin
biliou
ascit
rais
suspicion
bile
leak
biliari
strictur
site
anastomosi
also
present
fever
abdomin
pain
also
jaundic
asymptomat
biochem
cholestasi
biloma
repres
addit
sourc
infect
hepat
arteri
thrombosi
although
common
live
donor
liver
transplant
ldlt
uncommon
deceas
donor
liver
transplant
ddlt
overal
incid
lead
complic
includ
hepat
abscess
necrosi
sepsi
graft
loss
vancomycinresist
enterococcu
faecium
vref
particular
concern
liver
transplant
pretranspl
colon
increas
rate
intraabdomin
bsi
transplant
fact
hospit
intens
care
unit
stay
longer
patient
vref
versu
vancomycinsensit
e
faecium
infect
liver
pancrea
intestin
recipi
particular
risk
fungal
infect
often
caus
candida
speci
regard
ddlt
versu
ldlt
variat
infecti
complic
rate
infect
appear
similar
ddlt
howev
complex
natur
surgeri
observ
differ
specif
concern
detail
box
clinic
syndrom
hepat
dysfunct
rang
mild
elev
liver
enzym
hepat
fulmin
hepat
failur
hepat
dysfunct
present
sot
recipi
howev
utmost
concern
would
liver
transplant
recipi
caus
rang
infecti
noninfecti
noninfecti
caus
primarili
issu
liver
transplant
recipi
regard
postop
complic
recurr
primari
diseas
druginduc
complic
reject
infecti
caus
list
fig
rang
donorderiv
infect
postop
complic
communityacquir
organ
reactiv
opportunist
pathogen
evalu
includ
imag
eg
ultrasound
comput
tomographi
mri
along
appropri
infecti
workup
eg
blood
cultur
serum
pcr
serolog
antigen
andor
antibodi
diagnosi
remain
inconclus
liver
biopsi
may
need
pursu
appropri
stain
obtain
diarrhea
follow
transplant
frequent
observ
estim
occur
patient
associ
allograft
loss
increas
mortal
fact
result
hospit
death
annual
sever
caus
diarrhea
lead
hypovolemia
andor
septic
shock
diarrhea
recogn
side
effect
immunosuppress
agent
howev
infecti
caus
consid
base
clinic
pictur
caus
detail
fig
evalu
includ
stool
cultur
ova
parasit
giardia
antigen
along
appropri
pcr
antigen
test
andor
special
stain
imag
may
includ
comput
tomographi
evalu
bowel
wall
edema
along
colon
wall
thicken
dilat
esophagogastroduodenoscopi
egd
andor
colonoscopi
along
biopsi
may
also
warrant
cmv
coliti
diagnos
via
histopatholog
obtain
biopsi
serum
pcr
low
undetect
set
clinic
suspicion
eg
elev
serum
pcr
along
diarrhea
howev
patient
unabl
undergo
colonoscopi
may
warrant
empir
treatment
clostridium
difficil
infect
cdi
among
common
health
careassoci
pathogen
common
caus
nosocomi
infecti
diarrhea
highest
incid
cdi
sot
occur
within
first
month
follow
transplant
like
relat
frequent
exposur
antimicrobi
health
care
set
immunosuppress
proton
pump
inhibitor
ppi
known
risk
cdi
may
still
use
set
mechan
ventil
versu
blocker
hospit
patient
use
ppi
twice
like
develop
cdi
fulmin
coliti
develop
sot
recipi
cdi
relaps
diseas
common
protract
cours
therapi
often
essenti
idsa
societi
healthcar
epidemiolog
america
recent
updat
clinic
practic
guidelin
clostridium
difficil
infect
adult
children
although
immunocompet
patient
guidelin
appli
sot
recipi
limit
studi
treatment
cdi
sot
patient
common
infecti
complic
sot
uti
account
infect
hospit
sepsi
ktr
uti
seen
within
first
month
transplant
howev
occur
time
transplant
empir
treatment
imper
demonstr
inappropri
antibiot
therapi
associ
increas
mortal
guid
empir
therapi
local
epidemiolog
data
patient
microbiolog
histori
prior
antibiot
use
need
taken
account
frequent
organ
caus
uti
gramneg
bacilli
howev
urinari
cathet
involv
enterococci
aureu
also
consid
durat
treatment
vari
day
depend
clinic
syndrom
recurr
uti
defin
episod
symptomat
uti
period
previou
month
prompt
investig
regard
anatom
function
abnorm
along
behavior
modif
eg
postcoit
void
may
need
prolong
cours
antibiot
possibl
week
asymptomat
bacteriuria
treat
earli
postop
period
month
transplant
renal
transplant
patient
data
uti
relat
candida
spp
sot
limit
mostli
includ
ktr
ktr
candida
spp
frequent
isol
fungal
caus
uti
unfortun
clinic
trial
manag
candida
uti
sot
candiduria
frequent
occur
ktr
howev
mostli
asymptomat
asymptomat
candiduria
usual
treat
concern
regard
allograft
potenti
complic
regard
upper
urinari
tract
howev
treat
patient
neutropen
undergo
urolog
procedur
candiduria
classifi
base
risk
factor
dissemin
candidiasi
urinari
cathet
remov
exchang
candiduria
confirm
second
clean
void
urin
cultur
dissemin
candidiasi
may
consid
clinic
manifest
consist
eg
posit
blood
cultur
second
urin
cultur
remov
replac
urinari
cathet
funduscop
examin
cultur
signific
site
kidney
imag
persist
candiduria
along
infecti
complic
indwel
cathet
prompt
imag
kidney
collect
system
exclud
renal
abscess
fungu
ball
urolog
abnorm
treatment
option
rang
fluconazol
treatment
choic
echinocandin
amphotericin
b
flucytosin
depend
clinic
situat
organ
sensit
durat
least
day
uti
week
pyelonephr
box
sot
recipi
complex
group
patient
divers
caus
given
underli
immunosuppress
infecti
process
rapid
identif
alway
consid
previou
microbiolog
data
local
epidemiolog
regard
empir
antibiot
intravascular
cathet
involv
consid
broad
gramposit
cocci
includ
mrsa
coverag
addit
broad
gramneg
coverag
includ
esbl
cre
warrant
empir
antifung
need
unless
high
index
suspicion
alway
consid
previou
microbiolog
data
local
epidemiolog
regard
empir
antibiot
cap
includ
empir
coverag
atyp
along
communityassoci
organ
hap
vap
includ
broad
gramposit
coverag
especi
mrsa
along
broad
gramneg
coverag
includ
esbl
cre
warrant
influenza
viru
approv
treatment
oseltamavir
therefor
start
empir
concern
antifung
start
empir
even
lung
transplant
recipi
howev
fungal
infect
work
thoroughli
pathogen
sourc
control
adjust
immunosuppress
hallmark
treatment
summari
manag
infect
sot
recipi
includ
box
empir
therapi
consist
ceftriaxon
vancomycin
ae
acyclovir
alway
consid
previou
microbiolog
data
local
epidemiolog
regard
empir
antibiot
vre
posit
need
consid
coverag
use
highdos
daptomycin
linezolid
along
broad
gramneg
coverag
includ
esbl
cre
warrant
regard
c
difficil
infect
oral
vancomycin
initi
empir
suspect
firstlin
therapi
alway
consid
previou
microbiolog
data
along
local
epidemiolog
regard
empir
antibiot
decis
asymptomat
bacteriuria
treat
renal
transplant
patient
first
month
posttransplant
antimicrobi
tailor
caus
agent
durat
gener
rang
day
depend
clinic
context
fluconazol
treatment
choic
cystiti
pyelonephr
candida
caus
organ
abbrevi
cre
carbapenemresist
enterobacteriacea
esbl
extend
spectrum
betalactamas
inhibitor
vap
ventilatorassoci
pneumonia
